Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Horus Pharma selected as additional commercialization partner for aflibercept biosimilar in Europe | Ophthalmology Times
(Image credit: AdobeStock) Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global commercialization rights of Formycon’s Eylea1 biosimilar FYB203 (aflibercept), issued an additional semi-exclusive license agreement with Horus Pharma for the commercialization of FYB203/Baiama 2 in selected European countries.1…
Q&A: Stela Vujosevic shares why the staging system for diabetic eye conditions should be updated | Ophthalmology Times
Photo of Stela Vujosevic at the 2025 EURETINA meeting in Paris, France Stela Vujosevic, Md, PhD, FEBO, presented the need for a new staging system for diabetic retinopathy and diabetic macular edema at the 2025 EURETINA meeting in Paris, France.…
ExSight Ventures invests in RevOpsis Therapeutics to further AMD treatment candidate | Ophthalmology Times
Image credit: AdobeStock/jirsak ExSight Ventures invested in RevOpsis Therapeutics, a company developing a novel class of multispecific antibody-based treatments designed to address significant unmet needs in ophthalmology. The company states that initial focus will be on the developing treatment for…
Investigators share positive results of DAVIO 2 trial at EURETINA 2025 | Ophthalmology Times
(Image credit: AdobeStock/THANANIT) EYP-1901, known as the vorolanib intravitreal insert, was highlighted at the EURETINA 2025 meeting, which was held in Paris, France. In 2 presentations, researchers shared the recent results from the DAVIO 2 clinical trial. What is EYP-1901?…
Kalaris enrolling phase 1b/2 study of TH103 for nAMD | Ophthalmology Times
(Image credit: ©kwanchaift/AdobeStock) Kalaris Therapeutics announced the company is currently enrolling a phase 1b/2 multiple ascending dose (MAD) study of TH103 for the treatment of neovascular age-related macular degeneration (nAMD).1 “The phase 1b/2 study represents an important milestone in advancing…
Timothy Lai on the SALWEEN trial
Photo of Timothy Lai, MD, at EURETINA 2025 in Paris, France Timothy Lai, a clinical professor honorary at the Department of Ophthalmology and Visual Sciences at the Chinese University of Hong Kong, presented the one-year data from the Salween study…
Global Spotlight: The Most Cost-Effective Countries for Cataract Surgery
Cataract surgery remains one of the most common and effective ophthalmic procedures globally, but the cost can be a significant barrier for many patients. In an increasingly interconnected world, medical tourism has emerged as a viable solution, offering high-quality, affordable…
UnitedHealthcare updates Glaucoma Surgical Treatments policy
(Image Credit: AdobeStock/gguy) UnitedHealthcare (UHC) has updated its Glaucoma Surgical Treatments policy to include goniotomy, trabeculotomy, canaloplasty (ab interno), combined canaloplasty (ab interno), and trabeculotomy procedures when deemed medically necessary for treating mild to moderate open-angle glaucoma (OAG) and cataracts…
Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa
(Image Credit: AdobeStock/Dmitrii Kotin) Beacon Therapeutics recently revealed topline data results for 2 of the company’s phase 2 trials—SKYLINE and DAWN, both investigating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP).1 The data was presented during the 2025…
Positive topline data announced from AVONELLE-X and SALWEEN trials
(Image credit: ©pressmaster/AdobeStock) Roche recently announced new data from the AVONELLE-X and SALWEEN trials of Vabysmo (faricimab).1 These trial data were presented at the 25th European Society of Retina Specialists (EURETINA) Annual Congress held September 4-7 in Paris. Positive safety,…